The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Open accessAbstract
BACKGROUND: The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority. METHODS: We conducted a single-center study, involving 176 adults, 18 to 50 years of age, to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted and nonadjuvanted forms. Subjects were randomly assigned to receive two intramuscular injections of vaccine containing 7.5 microg of hemagglutinin on day 0 in each arm or one injection on day 0 and the other on day 7, 14, or 21; or two 3.75-microg doses of MF59-adjuvanted vaccine, or 7.5 or 15 microg of nonadjuvanted vaccine, administered 21 days apart. Antibody responses were measured by means of hemagglutination-inhibition assay and a microneutralization assay on days 0, 14, 21, and 42 after injection of the first dose. RESULTS: The most frequent local and systemic reactions were pain at the injection site and muscle aches, noted in 70% and 42% of subjects, respectively; reactions were more common with the MF59-adjuvanted vaccine than with nonadjuvanted vaccine. Three subjects reported fever, with a temperature of 38 degrees C or higher, after either dose. Antibody titers, expressed as geometric means, were higher at day 21 among subjects who had received one dose of MF59-adjuvanted vaccine than among those who had received one dose of nonadjuvanted vaccine (P<0.001 by the microneutralization assay). By day 21, hemagglutination-inhibition and microneutralization antibody titers of 1:40 or more were seen in 77 to 96% and 92 to 100% of subjects receiving MF59-adjuvanted vaccine, respectively, and in 63 to 72% and 67 to 76% of those receiving nonadjuvanted vaccine, respectively. By day 42, after two doses of vaccine, hemagglutination-inhibition and microneutralization antibody titers of 1:40 or more were seen in 92 to 100% and 100% of recipients of MF59-adjuvanted vaccine, respectively, and in 74 to 79% and 78 to 83% of recipients of nonadjuvanted vaccine, respectively. CONCLUSIONS: Monovalent 2009 influenza A (H1N1) MF59-adjuvanted vaccine generates antibody responses likely to be associated with protection after a single dose is administered. (ClinicalTrials.gov number, NCT00943358).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903810 · Cited by 3,037
Strategies for mitigating an influenza pandemic
Ferguson, N. M., Cummings, D. A. T., Fraser, C., Cajka, J. C., Cooley, P. C., & Burke, D. S. (2006) · Nature · doi:10.1038/nature04795 · Cited by 2,187
Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in Mexico
Perez-Padilla, R., de la Rosa-Zamboni, D., Ponce de Leon, S., Hernandez, M., Quiñones-Falconi, F., Bautista, E., Ramirez-Venegas, A., Rojas-Serrano, J., Ormsby, C. E., Corrales, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904252 · Cited by 1,325
Rowe, T., Abernathy, R. A., Hu-Primmer, J., Thompson, W. W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 811
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 653
Katz, J. D., Hancock, K., Veguilla, V., Zhong, W., Lü, X., Sun, H., Butler, E. N., Dong, L., Liu, F., Li, Z. N., et al. (2009) · MMWR Morbidity and Mortality Weekly Report · Cited by 521
Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M., & Leroux-Roels, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61297-5 · Cited by 498
Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E., & Zambon, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05066-2 · Cited by 440
Self-citationStephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 285
Self-citation
Cited by
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Miller, E., Hoschler, K., Hardelid, P., Stanford, E., Andrews, N., & Zambon, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62126-7 · Cited by 708
Self-citationThe 2009 A (H1N1) influenza virus pandemic: A review
Girard, M. P., Tam, J. S., Assossou, O. M., & Kieny, M. P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.031 · Cited by 488
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 356
Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.-J., Baehner, F., Borkowski, A., Tsai, T. F., & Clemens, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010331 · Cited by 317
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Valenciano, M., Kissling, E., Cohen, J.-M., Oroszi, B., Barret, A.-S., Rizzo, C., Nunes, B., Pitigoi, D., Larrauri Cámara, A., Mosnier, A., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000388 · Cited by 303
Harnessing the beneficial heterologous effects of vaccination
Goodridge, H. S., Ahmed, S. S., Curtis, N., Kollmann, T. R., Levy, O., Netea, M. G., Pollard, A. J., van Crevel, R., & Wilson, C. B. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.43 · Cited by 258
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness
Furman, D., Jojic, V., Kidd, B., Shen‐Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H. T., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.15 · Cited by 184
Derhovanessian, E., & Pawelec, G. (2012) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00283.x · Cited by 51
Yang, J., Zhang, J., Han, T., Liu, C., Li, X., Yan, L., Yang, B., & Yang, X. (2020) · Medicine · doi:10.1097/md.0000000000019095 · Cited by 37
Metadata
- Authors
- Clark, T. W., Pareek, M., Hoschler, K., Dillon, H., Nicholson, K. G., Groth, N., & Stephenson, I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2424-2435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111299679
- Cited by
- 445
- References
- 22
- FWCI
- 63.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.